Biological validation that SF3b is a target of the antitumor macrolide pladienolide. - Wikidata - awgldk - TriplyDB

Biological validation that SF3b is a target of the antitumor macrolide pladienolide.

Biological validation that SF3b is a target of the antitumor macrolide pladienolide.

http://www.wikidata.org/entity/Q39461667

about

Modulating splicing with small molecular inhibitors of the spliceosome Myeloid malignancies: mutations, models and management Microbial and Natural Metabolites That Inhibit Splicing: A Powerful Alternative for Cancer Treatment Identification of hub genes of pneumocyte senescence induced by thoracic irradiation using weighted gene co‑expression network analysis Recent advances in the understanding of myelodysplastic syndromes with ring sideroblasts.Targeting Splicing in the Treatment of Myelodysplastic Syndromes and Other Myeloid Neoplasms.High antitumor activity of pladienolide B and its derivative in gastric cancer Identification of small molecule inhibitors of pre-mRNA splicing.Role of the splicing factor SRSF4 in cisplatin-induced modifications of pre-mRNA splicing and apoptosis Targeting the spliceosome in chronic lymphocytic leukemia with the macrolides FD-895 and pladienolide-B.SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts.Twelve-membered macrolactones: privileged scaffolds for the development of new therapeutics.Jerantinine A induces tumor-specific cell death through modulation of splicing factor 3b subunit 1 (SF3B1)Functions of Replication Protein A as a Sensor of R Loops and a Regulator of RNaseH1 Enantioselective total synthesis of pladienolide B: a potent spliceosome inhibitor Ruthenium-Catalyzed Olefin Metathesis after Tetra-n-butylammonium Fluoride-Mediated Desilylation.Functional Genomic Screening Reveals Splicing of the EWS-FLI1 Fusion Transcript as a Vulnerability in Ewing Sarcoma.Genomics-guided discovery of thailanstatins A, B, and C As pre-mRNA splicing inhibitors and antiproliferative agents from Burkholderia thailandensis MSMB43 Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins.RNA splicing factors as oncoproteins and tumour suppressors.Coherence between cellular responses and in vitro splicing inhibition for the anti-tumor drug pladienolide B and its analogs.Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival.Spliceosome and other novel mutations in chronic lymphocytic leukemia and myeloid malignancies.Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders.Splicing in oncogenesis and tumor suppression.The development and application of small molecule modulators of SF3b as therapeutic agents for cancer.Spliceosome mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia.Acquired mutations that affect pre-mRNA splicing in hematologic malignancies and solid tumors.Splice factor mutations and alternative splicing as drivers of hematopoietic malignancy.Design and synthesis of analogues of natural products.SF3B4 is decreased in pancreatic cancer and inhibits the growth and migration of cancer cells.Discoveries, target identifications, and biological applications of natural products that inhibit splicing factor 3B subunit 1.Splicing inhibition decreases phosphorylation level of Ser2 in Pol II CTD.Therapeutic targeting of splicing in cancer.Splicing factor gene mutations in hematologic malignancies.Splicing Factor Mutations in Myelodysplasias: Insights from Spliceosome Structures.A genome-wide siRNA screen for regulators of tumor suppressor p53 activity in human non-small cell lung cancer cells identifies components of the RNA splicing machinery as targets for anticancer treatment.Stabilized cyclopropane analogs of the splicing inhibitor FD-895 Structure of FD-895 revealed through total synthesis Splicing modulators act at the branch point adenosine binding pocket defined by the PHF5A-SF3b complex.

P2860

Q26738664-1360370D-0339-4607-9333-21583F32A628 Q27000577-4C4D4D4B-64DF-49D4-92CE-83DFEB88438B Q28074931-10DDF1FF-40E3-47AC-BB56-BC50D7F9DB98 Q28396973-615B31A9-11CC-4C6D-B2F8-BAC724C8A253 Q30249108-4C8D3E22-9663-45B3-83CA-FBFBE71E76F6 Q34047259-66C96731-3CE5-4B02-9AE6-E958000B1E6D Q35051717-648E59E6-48A5-4A50-8489-C57FD53F9A04 Q35301222-DA1243AB-187E-412B-A02B-7F07B6864C11 Q35442986-09EBCA4A-5B0E-4DD0-8D21-9696FFEC62A1 Q35800840-C953B5CC-9E62-47CE-979C-96BFBDD67C57 Q35925679-384C473E-DD77-480B-B835-B3F2A5E0F75A Q36011215-71EDF98C-2539-4278-A002-81A274FCAFB8 Q36280761-47E83A32-ED3F-4E13-8927-838E3C265B65 Q36296996-9A3610E7-16D8-4FE0-8ECA-DDC3EC3E8A23 Q36351397-73904B8E-9D5D-48A4-BD55-8FBB2EEB176F Q36485554-C2465EBA-4EF2-4B4F-92A4-A54A89BA6B1D Q36584775-90107A61-A98F-4A32-978D-89D89212FB79 Q36966213-8DB1FA55-60C8-4702-8059-77567F9ED08B Q36984373-C39D3DBA-725B-48A7-AC3D-1CDAB7BEB1F2 Q37391660-FB5DE41D-9D44-433A-9DBB-8C64E24D9DE2 Q37511674-0D1BCE76-4360-464B-8E29-388A4F84313D Q37628912-654D8DE3-8C68-4CFC-8CE8-FF5A45863B48 Q38000919-A595FE89-7180-4F13-9CF6-43ED61F64D0C Q38017093-E28E978F-3F74-41AA-A984-49D9F21E57CF Q38018123-7E53627E-935F-43A8-A4DA-ACBF0929A18A Q38033985-0B567E58-6B63-4C14-A91B-25381A986FC8 Q38074757-38AC9EB7-3893-4330-A18C-83B12F0B4463 Q38139915-2975FF71-E8AE-4FAE-A40B-8CDFA793F3C6 Q38289057-9DFC68AB-B9D5-44C3-B916-7949449DD0D5 Q38398596-0E5413E8-49D4-43B3-B630-44E80FC03551 Q38709877-73EBF74A-81CA-44FB-93F7-FF2ACFDB941F Q38712211-154A6966-260A-4F91-8EB2-A0FA9CA859DD Q38935296-8A4C7AB5-8E66-428F-AB66-D0C0FD999165 Q38948363-A1E2610F-7A21-497B-89D1-8DB8E28D0A6A Q39035441-6FD83FE5-A28A-4A79-86DC-B4A2F154C5F6 Q39217354-C3EC9870-F4A4-454F-8C21-BB9EA776FCE4 Q40291299-D2421B8B-774F-40C1-A8BB-3CD859747DD8 Q41904675-0E0A9947-1CB2-44C4-A6F4-7B63050279B1 Q41907881-BA1B4D09-5C8E-4A03-BEBD-C5291461A730 Q42222741-6B748023-8213-4D09-A7AB-25F82F85B348

P2860

Biological validation that SF3b is a target of the antitumor macrolide pladienolide.

http://www.wikidata.org/entity/Q39461667

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Biological validation that SF3b is a target of the antitumor macrolide pladienolide.

@en

Biological validation that SF3b is a target of the antitumor macrolide pladienolide.

@nl

type

label

Biological validation that SF3b is a target of the antitumor macrolide pladienolide.

@en

Biological validation that SF3b is a target of the antitumor macrolide pladienolide.

@nl

prefLabel

Biological validation that SF3b is a target of the antitumor macrolide pladienolide.

@en

Biological validation that SF3b is a target of the antitumor macrolide pladienolide.

@nl

P1433

Q39461667-9280C910-3D95-4F4A-A329-B15398E0A759

P1476

Q39461667-A14FA95F-977D-425F-8A5D-94473E63725B

P2093

Q39461667-0FDD0148-2F32-439C-B6B3-E2B2919C3BDA

Q39461667-27945F94-7C58-483D-8F3F-8C4171CA01D7

Q39461667-3B804010-50CF-4C47-9881-1CA83952E4E9

Q39461667-3EEC5AEA-15AC-43D4-8A80-D8C95EEADA41

Q39461667-641C09F3-0116-4ED5-A6BF-EA49B830F6C4

Q39461667-A84BBC36-DC6F-4A58-B1D4-9D9922120C92

Q39461667-E3D5740A-277E-451D-BFEC-99C908DFC813

Q39461667-ECD61EF5-9295-47DD-8742-4BEAD8343ACF

Q39461667-EDBD72C6-B054-4131-90D5-70056F3C609C

Q39461667-F8EA5010-7584-4353-95A8-178F39FA41CE

P2860

Q39461667-048B0BA5-676A-4EC1-9786-E111EC0C1D7D

Q39461667-28F7A7BC-FE24-47A2-B097-6FB511155578

Q39461667-2FC66862-BC20-4636-997C-7C8F6E23512F

Q39461667-3583E2F7-8D5D-469D-B9DF-8B33EA7F6B8B

Q39461667-53E726D1-E4F1-40C9-93CC-168DFAC9CCFB

Q39461667-5F884D17-02E1-4C68-A6E2-4A1094F10674

Q39461667-614B070D-B3DB-4712-B638-5D4E371C2E1A

Q39461667-62C4C241-9266-42F9-866D-E7207C66D785

Q39461667-768D890C-ECB4-49B7-BF14-F87DF7339A2C

Q39461667-828421E0-D6B0-4446-8EFB-1289B2E3BBE9

P304

Q39461667-1893CC72-1A4B-4EFD-A27A-BDF90707EEBA

P31

Q39461667-FB25C395-0E9C-41A5-BA56-37CF871AAF0B

P356

Q39461667-3F8334A8-F0B5-4D70-A11A-FE510179E8B3

P407

Q39461667-633A75B1-0AC2-40A0-814C-4BFB46724F5B

P433

Q39461667-2FE83A2D-E2AF-49D0-B1A0-7B221D42B482

P478

Q39461667-6AAC527B-9A78-414D-8990-0D09EC2DB35A

P50

Q39461667-3FC324C1-A7BD-4D8D-852E-B745C2699D12

P577

Q39461667-49F5B697-FF25-4388-AB7A-13C64DB8A34F

P5875

Q39461667-6DAE6CE2-DB94-4167-90AD-DAD66857BCF6

P698

Q39461667-8F5A3310-2269-4236-8EA0-21FADBCBBDCA

P356

J.1742-4658.2011.08387.X

P1433

P1476

Biological validation that SF3b is a target of the antitumor macrolide pladienolide.

@en

P2093

Akira Yokoi

http://www.w3.org/2001/XMLSchema#string

Kentaro Takahashi

http://www.w3.org/2001/XMLSchema#string

Makoto Hamaguchi

http://www.w3.org/2001/XMLSchema#string

Masao Iwata

http://www.w3.org/2001/XMLSchema#string

Naoko H Sugi

http://www.w3.org/2001/XMLSchema#string

Tadashi Kadowaki

http://www.w3.org/2001/XMLSchema#string

Yoshiharu Mizui

http://www.w3.org/2001/XMLSchema#string

Yoshihiko Kotake

http://www.w3.org/2001/XMLSchema#string

Yoshiko Matsumoto

http://www.w3.org/2001/XMLSchema#string

Yukinori Minoshima

http://www.w3.org/2001/XMLSchema#string

P2860

The structure of the protein phosphatase 2A PR65/A subunit reveals the conformation of its 15 tandemly repeated HEAT motifs

Characterization of a protein complex containing spliceosomal proteins SAPs 49, 130, 145, and 155

Molecular cloning, genetic mapping, and expression of the mouse Sf3b1 (SAP155) gene for the U2 snRNP component of spliceosome

Characterization of novel SF3b and 17S U2 snRNP proteins, including a human Prp5p homologue and an SF3b DEAD-box protein

Phosphorylation of spliceosomal protein SAP 155 coupled with splicing catalysis

A potential role for U2AF-SAP 155 interactions in recruiting U2 snRNP to the branch site

A novel U2 and U11/U12 snRNP protein that associates with the pre-mRNA branch site.

Combined biochemical and electron microscopic analyses reveal the architecture of the mammalian U2 snRNP

Structure of importin-beta bound to the IBB domain of importin-alpha

A conserved HEAT domain within eIF4G directs assembly of the translation initiation machinery

P304

4870-4880

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1742-4658.2011.08387.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

278

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-10-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51700910

http://www.w3.org/2001/XMLSchema#string

P698

21981285

http://www.w3.org/2001/XMLSchema#string